Many people think that Microdosing Iboga is addictive, but it is not. Actually its main function is to interrupt addiction. In addition, it develops a symptom-free opportunity and sometimes it acts as a catalyst for personal transformation. Post-treatment care plays a vital role when it comes to long-term recovery.
Psychoactive effects of Microdosing Iboga
Iboga is commonly known as a psychedelic drug. We can break down the experience of the drug in two phases, the introspection phase and the visionary phase. The visionary phase is oneirogenic, meaning the dreamlike nature of the psychedelic effects, and can last up to six hours. Introspection phase is the second phase, it causes psychotherapeutic effects. It lets people fight off their fears and negative emotions. Iboga also stimulates an altered state of consciousness making you dream while you are conscious and aware so that life experiences, memories, as well as problems of trauma can easily be processed.
One of the first effects of excess dosage of iboga is ataxia, which is a condition where a person has issues with muscle movement which makes walking and standing more difficult without assistance. Dry mouth, vomiting and nausea, may accompany that. These symptoms may take long time, somewhere between 4 and 24 hours in some instances. Sometimes, Iboga is given per rectum to avoid vomiting and nausea.
Cardiovascular and respiratory
In one study, microdosing iboga was found to increase the level of sinus arrhythmia. It was the advised that there is risk of QT-interval prolongation due to administration of the drug. The risk was proved by a case report indicating prolonged QT interval as well as ventricular tachycardia after taking the drug. Death as a result of iboga ingestion are written in medical literature. Cardiac and lethal respiratory effects are linked to its use.
In human beings, microdosing iboga is supposed to be in dosages starting from 5mg/kg of body the weight more so for a mild effect to 30mg/kg in treating strong addition Efficacy of dosages more than 30mg/kg is not known. In the study of animal neurotoxicity, there was no indication of neurotoxicity of iboga at 25 mg/kg. However, at 50mg/kg, more than 1/3 had patches of neuro-degeneration on them. But at doses of 75mg/kg and more, all rats displayed a common pattern of degeneration of what is known as Purkinje neurons, which was observed in the cellebum.
For more than thirty years, researchers, experts as well as health care providers have strived to study the various effects of Iboga as a treatment for alcohol, drug, as well as nicotine addiction, not forgetting psychological problems such as eating disorders and depressions. However, in the modern world that we live in, there is no doubt about the unparalleled effects of microdosing Iboga as an interrupter for addiction. However, for the treatment to completely get rid of the addiction, it has to be put in the context of a recovery program that caters for both emotional and physical healing of the addiction.